Compare Alliant Energy Corporation (LNT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Moderna, Inc. — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.6× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Moderna, Inc. for 59 Days on average.
| LNT | MRNA | |
|---|---|---|
Market Cap | $16.99B | $78.65B |
Volume | 2,488,387 | 37,373,437 |
Sector | Utilities | Health |
52-Week High | $78.03 | $225.00 |
52-Week Low | $63.21 | $22.36 |
Typical Hold Time | 64 Days | 59 Days |
Enterprise Value | $29.08B | $74.80B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.50, up 0.44% today, with a bullish technical signal and support near $65. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains a strong net income margin of 18.45%. Recent news highlights a $1.4B partnership and institutional buying, while a $13.4B capital expenditure plan supports long-term growth.
Outlook is positive with a consensus price target of $77, implying 17.6% upside, driven by steady utility demand and data center growth. Risks include rising debt levels and cost pressures. Analysts are bullish with 52% buy ratings, but investors should monitor execution of the capex plan and interest rate impacts.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
